NASH Diagnostics Segmentation
Type (Serums Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers)
The global nonalcoholic steatohepatitis diagnostics market is segmented and analyzed for demand and supply by type into Serum Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers and Others. Out of the five, the Serum Biomarkers segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed as serum biomarkers of liver function that precisely target the development and degradation of collagens, the critical components of fibrotic tissue, have a diverse advantage over traditional secondary biomarkers such as alanine transaminase and aspartate transaminase because they directly imitate the dynamics of hepatic fibrogenesis providing a substantial reason for their adoption. For instance, some serum indicators utilized in analyzing NASH include CK-18-M30, IL-1Ra, and FGF-21. Elevations of CK-18-M30 might be signs of active NASH. It has been demonstrated that CK-18-M30 levels rise as NASH and fibrosis stages advance.
End-user (Pharma & CRO, Hospitals, Academic Research Institutes)
The global nonalcoholic steatohepatitis (NASH) diagnostics market is also segmented and analyzed for demand and supply by end-user into Pharma & CRO Industry, Hospitals, Academic Research Institutes, and Others. Amongst these four segments, the pharma & CRO industry segment is expected to garner a significant share. The growth can be attributed to the extensive research activities being carried out by the pharma & CRO companies. For instance, Madrigal Pharmaceuticals, Inc. is researching whether 80 or 100 mg of MGL-3196, when compared to a placebo, can treat NASH, lessen liver biopsy fibrosis, and stop the progression of advanced liver disease such as cirrhosis.
Our in-depth analysis of the global prednisone market includes the following segments:
|
By Type |
|
|
By End User |
|
